Evidence map›Paper›PMID 28621526›Full record

ArticleAnalytical chemistry2017

Orthogonal Mass Spectrometry-Based Footprinting for Epitope Mapping and Structural Characterization: The IL-6 Receptor upon Binding of Protein Therapeutics.

Ke Sherry Li, Guodong Chen, Jingjie Mo, Richard Y-C Huang, Ekaterina G Deyanova, Brett R Beno, Steve R O'Neil, Adrienne A Tymiak, Michael L Gross

Open access · greenAbstract read
In one paragraph

Article in Analytical chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Article
  3. Toward a MALDI in-source decay (ISD) method for top-down analysis of protein footprinting.European journal of mass spectrometry (Chichester, England) · 2023
    Article
  4. MALDI Peptide Mapping for Fast Analysis in Protein Footprinting.International journal of mass spectrometry · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Investigation of D76N βJournal of the American Society for Mass Spectrometry · 2021
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ke Sherry LiDepartment of Chemistry, Washington University , St. Louis, Missouri 63130, United States.
Guodong ChenBioanalytical and Discovery Analytical Sciences, Pharmaceutical Candidate Optimization, Research and Development, Bristol-Myers Squibb , Princeton, New Jersey 08540, United States.
Jingjie MoBioanalytical and Discovery Analytical Sciences, Pharmaceutical Candidate Optimization, Research and Development, Bristol-Myers Squibb , Princeton, New Jersey 08540, United States.
Richard Y-C HuangBioanalytical and Discovery Analytical Sciences, Pharmaceutical Candidate Optimization, Research and Development, Bristol-Myers Squibb , Princeton, New Jersey 08540, United States.
Ekaterina G DeyanovaBioanalytical and Discovery Analytical Sciences, Pharmaceutical Candidate Optimization, Research and Development, Bristol-Myers Squibb , Princeton, New Jersey 08540, United States.
Brett R BenoMolecular Discovery Technologies, Research and Development, Bristol-Myers Squibb , Wallingford, Connecticut 06492 United States.
Steve R O'NeilMolecular Discovery Technologies, Research and Development, Bristol-Myers Squibb , Wallingford, Connecticut 06492 United States.
Adrienne A TymiakBioanalytical and Discovery Analytical Sciences, Pharmaceutical Candidate Optimization, Research and Development, Bristol-Myers Squibb , Princeton, New Jersey 08540, United States.
Michael L GrossDepartment of Chemistry, Washington University , St. Louis, Missouri 63130, United States.ORCID 0000-0003-1159-4636
Bristol-Myers Squibb (United States) · USWashington University in St. Louis · US

Funding

TrainingP41GM103422 · NIGMS · WASHINGTON UNIVERSITY · PI YARASHESKI, KEVIN E · 2012 to 2019
$12.0M
A MASS SPECTROMETER FOR PROTEIN FOOTPRINTINGS10OD016298 · OD · WASHINGTON UNIVERSITY · PI GROSS, MICHAEL L · 2014 to 2014
$450k
NIGMS NIH HHS P41 GM103422NIH HHS S10 OD016298
6 · The paper itself

Abstract

Higher-order structure (HOS) is a crucial determinant for the biological functions and quality attributes of protein therapeutics. Mass spectrometry (MS)-based protein footprinting approaches play an important role in elucidating the relationship between protein biophysical properties and structure. Here, we describe the use of a combined method including hydrogen-deuterium exchange (HDX), fast photochemical oxidation of proteins (FPOP), and site-specific carboxyl group footprinting to investigate the HOS of protein and protein complexes. The work focuses on implementing complementary solution-phase footprinting approaches that differ in time scale, specificity for protein residue side chains vs backbone as well as selectivity for different residue types to map integratively the epitope of human interleukin-6 receptor (IL-6R) for two adnectins with distinct affinities (K

Indexed as

Epitope MappingProtein FootprintingDeuterium Exchange MeasurementHumansMass SpectrometryProtein BindingProtein ConformationReceptors, Interleukin-6Receptors, Interleukin-6

Identifiers

PMID28621526
PMCPMC5549780
OpenAlexW2625717648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.